Company

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication.

On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. 

TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.

Read more...

Products

Read more...

Latest News

2 August 2016 - Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR)

20 July 2016 - Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix (EN - NL)

5 July 2016 - Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR)

5 July 2016 - TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms (EN - NL - FR)

17 June 2016 - TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction (EN - NL - FR)

Read more...

Company slide deck

2016 - Corporate Presentation

Management presentations

Full Year 2015 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014